NDAINHALATIONFOR SOLUTION
Approved
Feb 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
CAYSTON (aztreonam) by Gilead Sciences is 12. Approved for cystic fibrosis. First approved in 2010.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAYSTON (aztreonam) is a monobactam antibiotic administered via inhalation for the treatment of respiratory symptoms in cystic fibrosis (CF) patients chronically infected with Pseudomonas aeruginosa. The drug works by binding to penicillin-binding proteins in susceptible bacteria, inhibiting cell wall synthesis and leading to bacterial cell death. Administered as a 75 mg inhalation solution three times daily, CAYSTON delivers high local concentrations directly to CF lung tissue while maintaining low systemic absorption. It represents a targeted approach to managing chronic P. aeruginosa airway colonization, a major driver of morbidity in CF populations.
$0.0BPart D
Mechanism of Action
12.1 Mechanism of Action Aztreonam is an antibacterial drug [see ] . 12.3 Pharmacokinetics Sputum Concentrations Sputum aztreonam concentrations exhibited considerable variability between patients receiving CAYSTON (75 mg) in clinical trials. The mean sputum concentration 10 minutes following the…
Worked on CAYSTON at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.